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Elevated expression and activation of the focal adhesion kinase
(FAK) occurs in a large proportion of human breast cancers.
Although several studies have implicated FAK as an important
signaling molecule in cell culture systems, evidence supporting a
role for FAK in mammary tumor progression is lacking. To directly
assess the role of FAK in this process, we have used the Cre/loxP
recombination system to disrupt FAK function in the mammary
epithelium of a transgenic model of breast cancer. Using this
approach, we demonstrate that FAK expression is required for the
transition of premalignant hyperplasias to carcinomas and their
subsequent metastases. This dramatic block in tumor progression
was further correlated with impaired mammary epithelial prolif-
eration. These observations provide direct evidence that FAK plays
a critical role in mammary tumor progression.
breast cancer  Cre recombinase  transgenic
Cross-talk between integrin receptors and activated growthfactor receptors has been hypothesized to play a critical role in
the initiation and progression of cancer (1). Numerous in vitro
studies have documented the importance of integrin receptors and
their associated signaling molecules, including integrin-linked ki-
nase (ILK), focal adhesion kinase (FAK), and the Src family of
tyrosine kinases, in the regulation of cancer cell proliferation (2–4).
In this regard, using the Cre/loxP recombination system, we have
demonstrated that mammary epithelial ablation of 1-integrin
severely impaired tumor initiation in the polyomavirus middle T
(PyVmT) transgenic mouse model of breast cancer (5). Moreover,
the ablation of 1-integrin expression in established primary mam-
mary tumor cells was associated with a dramatic block in cell
proliferation (5). Interestingly, molecular and biochemical analyses
of the 1-integrin-null mammary tumor cells revealed that the
block of cancer cell proliferation was associated with a dramatic
decrease in FAK tyrosine phosphorylation (5). FAK is one of the
major components of focal adhesion complexes. It regulates inte-
grin-mediated cell adhesion and migration and is involved in the
control of cell proliferation and survival (6–8). In a normal
physiological context, engagement of integrin receptors by extra-
cellular matrix proteins results in the rapid activation of Src and
tyrosine phosphorylation of FAK (3, 4). FAK, in turn, phosphor-
ylates downstream substrates, such as paxillin, on tyrosine residues
and facilitates the recruitment of scaffold proteins like p130Cas (6).
Several reports have shown that FAK is overexpressed in differ-
ent types of cancer, with its levels of expression often associated
with advanced disease (7, 9). In vivo, the importance of FAK in
tumorigenesis was established in a study in which fakwas selectively
deleted in the epidermis. This conditional ablation of FAK resulted
in the complete block in the progression of benign papilloma lesions
to malignant carcinomas in a skin carcinogenesis model (10). There
is an increasing body of evidence implicating FAK activation in the
pathogenesis of human breast cancer. For instance, elevated ex-
pression of FAK has been associated with malignant transforma-
tion in human breast cancers (11, 12). Also, overactivation of FAK
has been observed in numerous established breast cancer cell lines
(13–15). To date, however, there is no direct in vivo evidence linking
FAKexpression and activation tomammary tumorigenesis. For this
purpose, conditional floxed (loxP-flanked) fak alleles were intro-
duced into MMTV-Cre/-PyVmT mice. This strategy allowed us to
further elucidate the relative contribution of FAK as a downstream
effector of integrins in PyVmT-induced mammary tumorigenesis.
By contrast tomammary-specific deletion of1-integrin,mammary
hyperplasias lacking FAK expression could be readily detected.
However, targeted disruption of FAK prevented progression of
these hyperplastic lesions to carcinomas. Our results suggest that
FAK function plays a critical role in mammary tumor progression.
Results
Mammary-Specific Disruption of FAK Does Not Interfere with the
Initial Stages of Mammary Ductal Outgrowth. Given the potential
importance of FAK in mammary tumor progression, we first
assessed whether mammary epithelial-specific ablation of FAK
would impact normal mammary gland development. To accom-
plish this, we interbred conditional FAK knockout mice (10) to
MMTV-Cremice (5, 16), in which theCre recombinase is under the
transcriptional control of the mouse mammary tumor virus
(MMTV) promoter/enhancer. We have confirmed that the
MMTV/Cre transgene is specific to the luminal mammary epithe-
lial cell compartment by breeding these mice to a Cre-inducible
GFP reporter strain (17, 18). Immunofluorescence analyses of
wholemounts derived from6-week-old femalemicewith antibodies
directed against myoepithelial keratin 14 or luminal keratin 8
markers revealed that GFP expression was detected sole in the
luminal epithelial compartment [supporting information (SI) Fig.
6]. Whole-mount analyses on mammary glands from 4-, 6-, and
8-week-old MMTV-Cre virgin mice heterozygous or homozygous
for a floxed fak allele (FAKflox/wt or FAKflox/flox) were then per-
formed. Examination of mammary glands from these animals
revealed that ablation of one or both fak alleles had no effect on the
initial mammary ductal outgrowth (SI Fig. 7). To ensure that the
absence of a mammary gland phenotype was not due to the lack of
efficient Cre-mediated FAK deletion in the mammary epithelium,
we performed both PCR and immunoblot analyses on whole
mammary gland tissues from 6- to 8-week-old virgin animals (SI
Fig. 8). The results demonstrate that mice carrying theMMTV-Cre
transgene and one or both conditional floxed fak alleles exhibited
evidence of fak excision (SI Fig. 8A) that correlated with a
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significant reduction in FAK protein levels (SI Fig. 8B). Moreover,
excision of one floxed fak allele is sufficient to cause a reduction in
FAK protein expression. Residual FAK expression reflects the
stromal contribution to FAK, given that the mammary epithelial
constitutes 20% of virgin gland. To confirm that the loss of
expression was restricted to the mammary epithelium, we per-
formed immunohistofluorescence analyses on mammary gland
paraffin sections using both Cre and FAK-specific antisera (SI Fig.
8C). In FAKflox/flox/MMTV-Cre mice, mammary epithelial cells
that were positive for Cre expression completely lacked detectable
FAK expression. As expected, mice heterozygous for the floxed fak
allele still retained some FAK protein staining. Careful quantifi-
cation of the number of ductal cells positive for Cre and lacking
FAK expression in FAKflox/flox/MMTV-Cre mice revealed that
64.3 15.6% (n 5) of the luminal epithelial cells had undergone
functional excision. Consistent with FAK immunostaining, intro-
duction of theGTRosa26Cre-responsive-galactosidase allele (19,
20) in FAKwt/flox/- and FAKflox/flox/MMTV-Cre mice revealed that
the majority of the mammary epithelium in mice homozygous for
the conditional floxed fak allele had undergone functional excision
as evidenced by robust X-Gal staining (SI Fig. 9). Taken together,
these observations suggest that FAK expression is dispensable for
the initial stages of normal mammary ductal outgrowth.
Targeted Disruption of FAK inMammary Epithelium Impairs Mammary
Tumor Development in the MMTV-PyVmT Mouse Tumor Model. We
next investigated whether mammary-specific disruption of FAK
would impact mammary tumor development. To accomplish this,
we interbred the conditional floxed FAK strain with mice express-
ing the PyVmT oncogene and Cre, both under the transcriptional
control of the MMTV promoter.
To determine whether a functional FAK was required for tumor
development, the MMTV-PyVmT transgene was introduced into
MMTV-Cre mice harboring either one or two copies of the floxed
fak allele (FAKflox/wt/MMTV-Cre/-PyVmT and FAKflox/f lox/
MMTV-Cre/-PyVmT mice, respectively). Cohorts of female mice
bearing these different genotypic combinations were subsequently
monitored formammary tumor development by physical palpation.
Compared with MMTV-Cre/-PyVmT mice bearing wild-type fak
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Fig. 1. Ablation of FAK expression increases the latency of mammary tumor
formation and results in fewer hyperplastic lesions in MMTV-PyVmT mice. (A)
Kinetics of mammary tumor onset in FAKwt/wt/-, FAKflox/wt/-, and FAKflox/flox/
MMTV-Cre/-PyVmT mice. The age indicated is that at which a mammary tumor
is first palpable in each transgenic strain. T50 denotes the age at which a tumor
is palpated in 50% of the mice. *, P 0.001 vs. FAKwt/wt mice, Student’s t test.
(B) Representative mammary gland whole mounts from 10-week-old virgin
FAKwt/wt/- (Left), FAKflox/wt/- (Center), and FAKflox/flox/- (Right) MMTV-Cre/-
PyVmT mice. (Scale bar: 5 mm.) Average mass (SEM) of inguinal mammary
glands from six, eight, and seven mice, respectively, for each strain is included.
*, P  0.01 vs. FAKwt/wt mice, Student’s t test. (C) Quantification of the area
occupied by hyperplastic lesions expressed as a percentage (SEM) of the total
mammary gland surface. Quantitative image analysis of the mammary gland
whole mounts was performed by using the Aperio ImageScope software. *,
P  0.001 vs. FAKwt/wt mice, Student’s t test.
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Fig. 2. FAK is not required for oncogenic transformation of the mammary
epithelium in the MMTV-PyVmT mouse model. (A) Mammary gland whole
mount from a 10-week-old FAKflox/flox/MMTV-Cre/-PyVmT/GTRosa26 mouse (rep-
resentative of n 4 animals) X-Gal-stained in situ for Cre-mediated -galactosi-
dase activity. Cre-expressing cells (blue) are present in untransformed ductal
structures (arrows). (Scale bar: 5 mm.) (B) A higher magnification of mammary
ductsshowinghyperplasticnodulesbothexpressingafunctionalCre(arrowhead)
or not (arrow). (Scale bar: 500 m.) Representative sections of X-Gal-stained
mammary glands from 10-week-old FAKwt/wt/MMTV-Cre/-PyVmT/GTRosa26 (n
3) (C) and FAKflox/flox/MMTV-Cre/-PyVmT/GTRosa26 (n 4) (D) mice. Solid nests of
tumor cells (asterisks) and hyperplastic regions of the epithelium (arrowheads)
are indicated. (Scale bar: 5 m.) (E and F) Representative X-Gal-stained cryosec-
tions of tumors from 12-week-old FAKflox/flox/MMTV-Cre/-PyVmT/GTRosa26 mice
(n  5). Unstained tumoral structures are indicated by asterisks. Stained non-
transformed ducts (arrows, E) and a group of stained preneoplastic structures
(arrowhead, F) are also indicated. (Scale bars: 10 m.)
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alleles, initial development of mammary tumors appeared to be
marginally delayed in MMTV-Cre/PyVmT mice homozygous for
the floxed fak allele by 1 week (Fig. 1A). Mice heterozygous for
the conditional fak allele also developed tumors with delayed onset,
albeit at an intermediate point between control and homozygous
floxed fak carriers (Fig. 1A). Consistent with these observations,
whole-mount analyses of mammary glands derived from these
cohorts at 6 and 10 weeks of age revealed that excision of both
floxed fak alleles resulted in a dramatic reduction in the number of
PyVmT-induced mammary hyperplastic lesions (SI Fig. 10A and
Fig. 1B). Quantitative measurements revealed that, compared with
the FAKwt/wt/MMTV-Cre/-PyVmT control animals, there was a
dramatic reduction both in the mammary gland average mass (SI
Fig. 10A and Fig. 1B) and in the percentage of the total mammary
gland area occupied by hyperplastic nodules in the FAKflox/flox/
MMTV-Cre/-PyVmT/ mice (SI Fig. 10B and Fig. 1C). Taken
together, these observations suggest that mammary-specific abla-
tion of FAK has an important impact on mammary tumor pro-
gression in the MMTV-PyVmT mice.
One potential explanation for the emergence of mammary
tumors in the ‘‘FAK-deficient’’ strain is that, because of the
stochastic expression of the MMTV-Cre transgene, there is a
selection for mammary epithelial that retain functional fak alleles
due toCre expression. Indeed, in our previous studies ofmammary-
specific deletion of1-integrin in the PyVmTmousemodel, tumors
that eventually arose were derived from this ‘‘escapee’’ population
ofCre-negativemammary epithelial cells (5). To test this possibility,
we introduced the GTRosa26 Cre-inducible -galactosidase re-
porter (5, 19, 20) into the different fak genetic backgrounds. This
strategy allowed us to follow the fate of individual Cre-expressing
cells during mammary tumorigenesis by staining mammary gland
whole mounts from 10-week-old virgin mice with X-Gal. As ex-
pected, the results revealed that in the FAKflox/flox/MMTV-Cre/-
PyVmT/GTRosa26 background, Cre-expressing cells were present
in the untransformed ductal structures (Fig. 2A). However, both
unstained (Fig. 2B, arrow) and X-Gal-stained (Fig. 2B, arrowhead)
mammary hyperplastic lesions were found in these mice. Histolog-
ical analyses allowed us to determine more precisely the pattern of
MMTV-Cre expression in the mammary glands of the FAKflox/flox/
MMTV-Cre/-PyVmT/GTRosa26 mice. Mammary gland sections
obtained from 10-week-old control FAKwt/wt/MMTV-Cre/-
PyVmT/GTRosa26 mice revealed cells stained with X-Gal in both
hyperplastic structures (Fig. 2C, arrowheads) and solid nests of
tumor cells (Fig. 2C, asterisks). By contrast, mammary-specific
deletion of FAK in age-matched glands resulted in induction of
mammary tumors that lacked robust X-Gal staining in solid tumor
regions (Fig. 2D, asterisks) but retained -galactosidase expression
in hyperplastic lesions (Fig. 2D, arrowheads). Consistent with these
observations, examination of mammary-gland sections obtained
from 12-week-old FAKflox/flox/MMTV-Cre/-PyVmT/GTRosa26 fe-
males (4- to 6-week tumor-bearing animals) showed that, whereas
late-stage tumors were uniformly-galactosidase-negative (Fig. 2E
and F, asterisks), only untransformed ductal structures (Fig. 2E,
arrows) or hyperplastic lesions (Fig. 2F, arrowhead) exhibited
evidence of homozygous deletion of FAK. Thus, these observations
suggest that emergence of the early hyperplastic lesions can occur
in the absence of FAK. However, given the lack of -galactosidase
expression in the carcinoma regions, these results suggest that FAK
A
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FAKflox/wt / MMTVCre / PyVmT
FAKwt/wt / MMTVCre / PyVmT
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B DAPI FAK/Cre
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*
Fig. 3. FAK deletion is restricted to MMTV-PyVmT hyperplasias. (A) Immuno-
histofluorescence analysis of Cre and FAK expression on paraffin sections of
mammary glands from 10-week-old FAKwt/wt/- (A Upper), FAKflox/wt/- (A Lower),
and FAKflox/flox/MMTV-Cre/-PyVmT (B) mice. Data are representative of at least
five animals of each genotype. FAK is coexpressed with Cre throughout the
MMTV-PyVmT-derived solid tumor tissue (A Upper). Note the reduced level of
FAK expression in the Cre-positive/FAKflox/wt tumoral cells. In FAKflox/flox glands,
Cre-positive/FAK-negative cells are detectable only in hyperplastic (B Upper) or
nontransformed ductal structures (B Lower, arrows). FAK expressing cells are
present in solid nests of tumor cells (B Lower, asterisk). (Scale bars: 20 m.)
FAKwt/wt/
GTRosa26 / MMTVCre / PyVmT /
FAKflox/flox/
GTRosa26 / MMTVCre / PyVmT /
+ X-Gal+ X-Gal
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Fig. 4. FAK-deleted cells do not contribute to lung metastasis in the MMTV-
PyVmT mouse model. Representative sections of X-Gal-stained lung lobes
from FAKwt/wt/- (Left) (n  8) and FAKflox/flox/- (Right) (n  6) MMTV-Cre/-
PyVmT/GTRosa26 mice bearing late stage tumors. -Gal-negative metastases
are indicated by arrowheads. Lower shows X-Gal-stained metastases at higher
magnification. [Scale bars: 50 m (Upper), 500 m (Lower).]
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expression is required for the conversion of these early lesions into
a fully malignant phenotype.
FAK-Deleted Cells Do Not Contribute to Either Mammary Carcinoma
Formation or Lung Metastasis. To confirm that FAK expression was
confined to hyperplastic lesions, we performed immunohistochem-
istry (SI Fig. 11) and immunofluorescence analyses on sections of
transformed mammary gland from mice wild-type, heterozygous,
or homozygous for the floxed fak allele using both FAK- and
Cre-specific antisera. Consistent with the X-Gal staining pattern
obtained (Fig. 2F), only early hyperplastic lesions retained expres-
sion of Cre in the samples fromFAKflox/flox mice (Fig. 3BUpper and
SI Fig. 11C Left). Moreover, coimmunostaining (Fig. 3) or staining
of sequential sections for FAK expression (SI Fig. 11) revealed that
these lesions have undergone efficient excision of the floxed fak
alleles. By contrast, examination of solid carcinoma areas revealed
an absence of Cre expression that was correlated with retention of
FAK staining (Fig. 3B Lower, asterisk, and SI Fig. 11C, asterisk).
Moreover, in the control FAKwt/wt and heterozygous FAKflox/wt
samples, these solid tumoral areas retain both Cre and FAK
expression although with a reduced level of FAK expression in the
FAKflox/wt mice (Fig. 3A and SI Fig. 11 A and B). These observa-
tions indicate that mammary hyperplastic cells lacking functional
copies of the fak allele could not contribute to carcinoma formation.
An important characteristic of PyVmT-induced mammary tu-
mors is that they frequently metastasize to the lung (21).Moreover,
FAKexpression and/or activity have been associatedwith increased
invasion and metastatic potential (6, 7, 22–24). To investigate
whether mammary-specific ablation of FAK can affect the metas-
tasis of PyVmT-induced mammary tumors, we first evaluated the
number ofmice that developed pulmonarymetastases as well as the
number ofmetastatic lesions per lung inMMTV-Cre/-PyVmTmice
homozygous for either the wild-type or floxed fak allele. The
percentage of 8-week tumor-bearing mice that developed lung
metastases was not significantly different between wild-type and
FAKflox/flox/MMTV-Cre/-PyVmTmice [93.3% (n 15) and 83.3%
(n 18), respectively]. Furthermore, the number ofmetastatic lung
lesions per lobe between the two groupswas the same (8.3 2.8 and
7.5  2.3, respectively). To assess whether these metastatic lesions
could derive from primary hyperplastic lesions lacking FAK, we
next examined both Cre and FAK expression patterns using X-Gal
and immunohistochemical staining of lungs harvested from wild-
type, heterozygous, or homozygous floxed fak PyVmT mice.
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Fig. 5. FAK-negative mammary epithelial neoplastic cells show a reduced proliferative capacity but do not exhibit any increase in apoptosis. Paraffin sections
of mammary gland from 6-week-old FAKwt/wt/-, FAKflox/wt/-, and FAKflox/flox/MMTV-Cre/-PyVmT mice were submitted to immunofluorescence analysis of Cre and
Ki67 (A) or activated caspase-3 (B) expression. [Scale bars: 50 m (A), 20 m (B).] Graphical representation of the immunostaining shown in A (C) and B (D).
Percentages (SEM) were calculated after counting multiple fields of at least five animals of each genotype. *, P  0.01 vs. FAKwt/wt mice, Student’s t test.
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PyVmT/GTRosa26mice revealed that these lungmetastatic lesions
readily stained blue in the presence of X-Gal (Fig. 4 Left). Indeed,
62.5  28.6% (n  5) of the lung lesions from control animals
expressed -galactosidase. Consistent with this finding, immuno-
histochemical staining of lung sections with specific antibodies
revealed both Cre and FAK expression among the metastatic
lesions in the wild-type animals (SI Fig. 12 A and B Left). By
contrast, none of the lung metastases from mice bearing both
conditional floxed fak alleles (n  8) exhibited either X-Gal
staining or Cre antibody labeling. Consistently, the metastatic
lesions lacking Cre expression retained robust FAK antibody
labeling (Fig. 4 Right and SI Fig. 12 A and B Right). However, lung
lesions from mice bearing a single conditional floxed fak allele
displayed both Cre and FAK immunostaining (SI Fig. 12 A and B
Center). Thus, just as the PyVmT-induced mammary carcinoma
development depended on the presence of FAK, the formation of
lung metastases in mice homozygous for the floxed fak allele also
requires the retention of functional FAK alleles.
Mammary-Specific Disruption of FAK Results in a Dramatic Reduction
in the Proliferative Potential of PyVmT Hyperplastic Cells. To inves-
tigate the observed defect in mammary tumor progression in the
FAK-deficient strains, we measured the proliferative potential of
hyperplastic mammary cells by performing coimmunofluorescence
staining of mammary gland sections using antibodies against both
Ki67, a conventional proliferation marker, and Cre. To ensure that
the mammary glands examined correspond to the early phases of
oncogenic transformation, we used only nontumor-bearing mice in
this analysis. We first assessed whether lack of FAK expression had
an impact on the proliferative potential of the MMTV-PyVmT
hyperplastic cells. The results showed that 50% of the Cre-
positive hyperplastic cells arising in wild-type mammary glands
exhibited robust Ki67 coimmunostaining (Fig. 5 A Top and C).
However, the number of Cre and Ki67 double-positive cells was
significantly lower in FAKflox/wt/MMTV-Cre/-PyVmT mammary
glands (Fig. 5 A Middle and C). Moreover, staining of sections
prepared from ‘‘FAK-deficient’’ glands exhibited a dramatic re-
duction (i.e., 16%) in the number of Cre-positive cells that also
expressed Ki67 (Fig. 5 A Bottom and C).
Using an identical approach, we looked at the apoptotic status of
these mammary glands by performing activated caspase-3 immu-
nostaining analyses. Unlike the strong defect in Ki-67 staining, the
Cre-positive hyperplastic cells observed on FAKflox/wt/- and FAK-
flox/flox/MMTV-Cre/-PyVmT cross-sections failed to exhibit evi-
dence of enhanced apoptotic rate (Fig. 5 B andD). Taken together,
these observations suggest that the dramatic defect in FAKflox/flox/
MMTV-Cre/-PyVmT tumor progression is caused by a lack of FAK
expression leading to a reduced proliferative capacity of PyVmT
tumor cells.
Discussion
Activation of FAK has been associated with breast cancer progres-
sion. Indeed, a large proportion of primary human breast cancers
possess elevated FAK expression that is further correlated with
malignant transformation (11, 12, 24) and poor clinical outcome
(22, 23). We demonstrate that targeted disruption of FAK in
mammary tumor cells can block progression of hyperplasias to full
carcinomas. We further show that this block in tumor progression
is correlated with a dramatic reduction in the ability of the
mammary tumor cells to proliferate. These observations provide
compelling evidence that activation of FAK plays a critical role in
mammary tumorigenesis.
Whereas targeted ablation of FAK negatively impacts on malig-
nant progression, mammary epithelial-specific loss of FAK did not
affect the initial stages of mammary gland outgrowth. This latter
observation contrasts a recent study where a similar mammary
gland FAK conditional knockout model was used to show that fak
deletion delays mammary ductal elongation and induces lactation
defects (25). This divergence is plausibly due to the different
background strains (C57BL/6) and MMTV-Cre transgenic mice
(line F) used. In our model, we have shown that the lack of an
obvious mammary ductal outgrowth defect was not due to absence
of efficient and functional excision of the conditional floxed fak
alleles, as evidenced by PCRanalysis, expression of-galactosidase,
and, finally, immunohistofluorescence analyses showing the pres-
ence of Cre and the lack of FAK expression in the mammary
epithelium. Consistent with these observations, mammary-specific
ablation of 1-integrin, which functions upstream of FAK, has also
been shown to have little phenotypic impact on the initial stages of
ductal outgrowth (5). However, mammary-specific ablation of
1-integrin during the later stages of differentiation resulted in
impairment of lactation due to an alteration of mammary epithelial
proliferation (26, 27). Although FAK ablation does not affect the
ability of mice to lactate, the impact of FAK disruption on the
proliferative potential of differentiated mammary epithelial re-
mains to be addressed.
Mice lacking a functional FAK develop mammary tumors, yet
there is a dramatic attenuation in the number of hyperplastic
lesions. Significantly, those homozygous floxed fak late-stage tu-
mors and their derived lung metastases arise from cells that do not
express Cre recombinase and thus have failed to undergo functional
excision of the floxed fak alleles. This suggests that FAK function
is critical formammary tumor progression in the PyVmT transgenic
mouse model. Consistent with these observations, we have dem-
onstrated that targeted disruption of 1-integrin results in a similar
block in tumor progression (5). However, unlike the 1-integrin-
deficient strains, mammary-specific deletion of FAK did not hinder
the emergence of preneoplastic adenomas. These observations are
consistent with the previous findings showing that conditional
deletion of fak in the epidermis interferes with the malignant
conversion of benign papillomas to carcinomas in a mouse skin
carcinogenesis model (10). One key difference between the skin
carcinogenesis model and PyVmT mammary tumor model is that
the inability of mammary hyperplasias to progress to carcinomas
was associated with a decrease in epithelial proliferation, whereas
the defect in skin tumorigenesis was associated with enhanced
apoptosis (10). Whether the disparity in the response of these
mouse tumor models to loss of FAK reflects intrinsic tissue
specificity or differences in the nature of the carcinogenic factor
used (chemical vs. oncogene) remains to be elucidated. However,
our data are consistent with results obtained using MTLn3 rat
mammary adenocarcinoma cells expressing FAK-related nonki-
nase (FRNK), a dominant-negative splice variant of FAK. Indeed,
in syngeneic tumors obtained after injection of these cells into the
mammary fat pad, van Nimwegen et al. (23) have shown that
FRNK-induced expression decreased the primary tumor growth
without causing apoptosis. It would also be interesting to assess
whether the observed decrease in proliferation could lead to
apoptotic cell death at later time points, because apoptosis was
assayed on mammary glands from 6-week-old animals.
The finding thatmammary-specific deletion of fak impacts on the
proliferative capacity of the PyVmT hyperplastic cells is consistent
with previous observations showing that mammary-specific abla-
tion of 1-integrin resulted in a proliferative arrest (5). Given the
phenotypic similarities between 1-integrin- and FAK-deficient
mammary tissues in the PyVmT mouse model, activation of FAK
appears to be one of the critical signaling events immediately
downstream of 1-integrin. Indeed, loss of 1-integrin is associated
with dramatic down-regulation of tyrosine phosphorylation of FAK
(5). However, given that the 1-integrin-deficient PyVmT mice
failed to develop mammary epithelial hyperplasias, whereas FAK-
deficient cells are still capable of forming hyperplastic lesions, there
must be other FAK-independent 1-integrin-coupled signaling
pathways that are also involved in mammary tumor formation. For
instance, the ILK pathway seems to be a very good candidate (2).
Wehave actually shown, using amammary-specific ILK conditional
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knockout mousemodel, that ILK deletion has significant effects on
PyVmT-induced mammary tumor progression without affecting
FAK activity (unpublished data).
Another interesting observation is that FAK-deficient hyperpla-
sias are still detectable as distinct entities in late-stage tumor
samples. Remarkably, this resembles the phenomenon of tumor
dormancy observed in T-Hep3 human carcinoma cells after inhi-
bition of FAK signaling (28).
The observation that FAK plays a critical role in tumor progres-
sion in the MMTV-PyVmT mouse tumor model may have impor-
tant therapeutic implications for the treatment of human breast
cancer. Given the large proportion of human breast cancers that
express elevated levels of FAK (11, 22), inhibition of FAK catalytic
activity with small-molecule inhibitors (29, 30)may be an important
strategy in themanagement of the disease. In this regard, there have
been several reports suggesting that inhibition of FAK can have a
profound effect on tumor growth and invasion (23, 24, 29, 31–33).
The future development of therapeutic reagents directed against
FAK and its coupled signaling pathways has excellent potential for
the treatment of primary breast cancers.
Methods
Transgenic Mice. MMTV-PyVmT, MMTV-Cre, and FAKflox mice were generated
and characterized as described (10, 16, 21). GTRosa26 mice were purchased from
The Jackson Laboratory and are described in refs. 5 and 19. The CAG-CAT-EGFP
reporter mice are described in refs. 17 and 18. To preclude the possible involve-
ment of genetic background variability, all transgenic mice used were derived
from the inbred FVB/N strain. Mammary tumor formation was monitored in
virgin mice by biweekly palpation. All experiments involving animals were con-
ducted in accordance with McGill University animal care guidelines.
Antibodies. Primary antibodies used in these experiments include rabbit poly-
clonal anti-FAK (06–543, Upstate Biotechnology), anti-Cre recombinase (PRB-
106C, Covance), anti-cleaved caspase-3 (9661, Cell Signaling), anti-cytokeratin 14
(PRB-155P, Covance), and mouse monoclonal anti-Ki67 (NCL-L-Ki67-MM1, Novo-
castra),anti-FAK(05–537,UpstateBiotechnology),anti-Cre (MMS-106P,Covance)
and anti--actin (AC-15, Sigma). Guinea pig polyclonal anti-cytokeratin 8/18
(RDI-PR0GP11) was purchased from Fitzgerald. The Alexa Fluor goat anti-guinea
pig 555 (A-21435), goat anti-mouse 555 (A-21422), 633 (A-21050), goat anti-
rabbit 555 (A-21428), and 633 (A-21070) antibodies were from Molecular Probes
(see SI Text).
Histological and Immunohistochemical Analysis of Tissue Sections. Thoracic
mammary glands or lung lobes were fixed in 10% neutral buffered formalin
(Surgipath) and transferred to 70% ethanol the next day. Samples were then
paraffin-embedded and sectioned at 5 m. Endogenous peroxidase activity was
blocked with 3% peroxide hydrogen in methanol. Antigen retrieval was accom-
plished in citrate buffer and by using a pressure cooker (Cuisinart). Sections were
then blocked with Power Block Universal Blocking Agent (Biogenex) and incu-
bated in primary antibody as described (5). Lungs were harvested from mice
bearing tumors for 8 weeks. Pulmonary metastases were identified by micro-
scopic analyses of hematoxylin/eosin-stained lung step sections. For immunoflu-
orescence analyses, sections were incubated with secondary antibodies for 1 h at
room temperature followed by incubation with DAPI (Sigma) for 10 min. They
were visualized by using a Zeiss LSM 510 META confocal microscope.
Mammary GlandWholeMounts and -Galactosidase Assay. Whole mounts were
prepared from the no. 4 inguinal mammary glands as described (5). For in situ
-galactosidase assay, no. 3 thoracic and no. 4 inguinal glands were processed as
described (5). For X-Gal staining of tumor cryosections, small pieces of tumors
were placed in plastic molds and frozen in Tissue-Tek OCT (Sakura) by using liquid
nitrogen.Samplesweresectionedat8musingaHM500OMmicrotomecryostat
(Microm). Sections were dried for 1 h at room temperature, fixed in PBS/0.2%
glutaraldehyde (Sigma) for 10 min, rinsed in PBS, and incubated in X-Gal staining
solution [2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet P-40, 5 mM
K4Fe(CN)6, 5 mM K3Fe(CN)6, and 1 mg/ml X-Gal (Invitrogen) in PBS (pH 7.4)]
overnight at 37°C. Sections were fixed again, rinsed, dehydrated through a
graded series of ethanol baths and xylenes, and mounted with Immu-mount
(Shandon). X-Gal-stained paraffin sections or cryosections were counterstained
with Nuclear Fast Red.
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